Pay-for-delay cannot be per se violation, says Third Circuit
The US Court of Appeals for the Third Circuit has ruled that pharmacies’ antitrust claims against Pfizer and Ranbaxy were correctly dismissed, due to the plaintiffs’ insistence that an allegedly anticompetitive reverse payment inherently violated California antitrust law.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10